CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

NIAID Data Ecosystem2026-03-11 收录

转移性结直肠癌治疗

化疗放疗方案

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2316883 数据链接链接失效反馈

官方服务：

资源简介：

The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

创建时间：

2019-10-15

The responses of individual organoid to different treatments: data for Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer

类器官药物测试

转移性结直肠癌治疗

The responses of individual organoid to different treatments (irradiation, 5-Fu and CPT-11): data for Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer.

NIAID Data Ecosystem70

An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

转移性结直肠癌治疗

贝伐珠单抗疗效评估

This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic c

NIAID Data Ecosystem40

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

转移性结直肠癌治疗

靶向药物疗效评估

The purpose of this study is to evaluate, in terms of overall survival, the benefit of monoclonal antibodies in the start time of the diagnosis of advanced disease or administer a deferred basis after

NIAID Data Ecosystem30

Supplementary Tables – FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study

癌症治疗评估

化疗放疗方案

Supplementary Table 1. Maintenance after FFN Supplementary Table 2. Locoregional treatment Supplementary Table 3. surgery after first line

DataCite Commons2022-05-24 更新40

Phase II study of dose-escalation of Regorafenib for patients with previously treated metastatic colorectal cancer.

转移性结直肠癌治疗

剂量递增研究

Interventions: Regorafenib is administered orally once daily for 21 days followed by 7 days rest. The initial dose of regorafenib is 80mg/day, and dose-escalation to 120mg or 160mg/day should be consi

NIAID Data Ecosystem40

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

资源简介：

相关数据集